This list is an analysis based on recent market events. It's not an investment recommendation.
About
Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Targovax AS stocks are traded under the ticker TA5.STU.
What is Targovax AS revenue for the last year?▼
Targovax AS revenue for the last year amounts to 0 EUR.
What is Targovax AS net income for the last year?▼
TA5.STU net income for the last year is -3.88M EUR.
How many employees does Targovax AS have?▼
As of September 04, 2026, the company has 9 employees.
In which sector is Targovax AS located?▼
Targovax AS operates in the Health & Wellness sector.
When did Targovax AS complete a stock split?▼
The last stock split for Targovax AS was on October 04, 2023 with a ratio of 1:30.